Carla Greenbaum1, Sandra Lord2, Dana VanBuecken2. 1. Benaroya Research Institute, Seattle, WA, USA. cjgreen@benaroyaresearch.org. 2. Benaroya Research Institute, Seattle, WA, USA.
Abstract
PURPOSE OF REVIEW: This review seeks to characterize emerging concepts related to disease-modifying therapy in type 1 diabetes. RECENT FINDINGS: We begin by describing the new understanding that islet autoimmunity, as identified by the presence of islet autoantibodies, inevitably leads to clinical type 1 diabetes. This understanding informs the new staging paradigm for type 1 diabetes, which suggests that type 1 diabetes may be recognized and diagnosed long before symptoms develop. Although it is known that nearly all individuals with established islet autoimmunity will eventually develop symptomatic type 1 diabetes (T1D), individual characteristics such as age and biomarker profile may predict rate of disease progression and response to treatment and may therefore be used to individualize therapy. Key research supports the use of immunotherapy in TID, although a paradigm shift is necessary before immunotherapy may transition from clinical trials to clinical practice. Recent and ongoing research as it relates to these concepts is described throughout.
PURPOSE OF REVIEW: This review seeks to characterize emerging concepts related to disease-modifying therapy in type 1 diabetes. RECENT FINDINGS: We begin by describing the new understanding that islet autoimmunity, as identified by the presence of islet autoantibodies, inevitably leads to clinical type 1 diabetes. This understanding informs the new staging paradigm for type 1 diabetes, which suggests that type 1 diabetes may be recognized and diagnosed long before symptoms develop. Although it is known that nearly all individuals with established islet autoimmunity will eventually develop symptomatic type 1 diabetes (T1D), individual characteristics such as age and biomarker profile may predict rate of disease progression and response to treatment and may therefore be used to individualize therapy. Key research supports the use of immunotherapy in TID, although a paradigm shift is necessary before immunotherapy may transition from clinical trials to clinical practice. Recent and ongoing research as it relates to these concepts is described throughout.
Entities:
Keywords:
Stages of type 1 diabetes; Type 1 diabetes disease course; Type 1 diabetes immunotherapy; Type 1 diabetes prevention; Type 1 diabetes research; Type 1 diabetes treatment
Authors: V Parikka; K Näntö-Salonen; M Saarinen; T Simell; J Ilonen; H Hyöty; R Veijola; M Knip; O Simell Journal: Diabetologia Date: 2012-03-23 Impact factor: 10.122
Authors: Stephen E Gitelman; Peter A Gottlieb; Mark R Rigby; Eric I Felner; Steven M Willi; Lynda K Fisher; Antoinette Moran; Michael Gottschalk; Wayne V Moore; Ashley Pinckney; Lynette Keyes-Elstein; Sudeepta Aggarwal; Deborah Phippard; Peter H Sayre; Linna Ding; Jeffrey A Bluestone; Mario R Ehlers Journal: Lancet Diabetes Endocrinol Date: 2013-08-28 Impact factor: 32.069
Authors: Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone Journal: Clin Immunol Date: 2009-05-14 Impact factor: 3.969
Authors: William A Hagopian; Henry Erlich; Ake Lernmark; Marian Rewers; Anette G Ziegler; Olli Simell; Beena Akolkar; Robert Vogt; Alan Blair; Jorma Ilonen; Jeffrey Krischer; JinXiong She Journal: Pediatr Diabetes Date: 2011-05-12 Impact factor: 3.409
Authors: Mark D Pescovitz; Carla J Greenbaum; Brian Bundy; Dorothy J Becker; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Jennifer B Marks; Antoinette Moran; Philip Raskin; Henry Rodriguez; Desmond A Schatz; Diane K Wherrett; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler Journal: Diabetes Care Date: 2013-09-11 Impact factor: 19.112
Authors: Diane K Wherrett; Jane L Chiang; Alan M Delamater; Linda A DiMeglio; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; Daniel J Lovell; Trevor J Orchard; Christopher M Ryan; Desmond A Schatz; David S Wendler; Carla J Greenbaum Journal: Diabetes Care Date: 2015-10 Impact factor: 19.112
Authors: Anne M Pesenacker; Virginia Chen; Jana Gillies; Cate Speake; Ashish K Marwaha; Annika Sun; Samuel Chow; Rusung Tan; Thomas Elliott; Jan P Dutz; Scott J Tebbutt; Megan K Levings Journal: JCI Insight Date: 2019-03-21
Authors: Li Zhang; Tomasz Sosinowski; Aaron R Cox; Joseph Ray Cepeda; Nitin S Sekhar; Sean M Hartig; Dongmei Miao; Liping Yu; Massimo Pietropaolo; Howard W Davidson Journal: J Autoimmun Date: 2018-08-16 Impact factor: 7.094
Authors: Melena D Bellin; Mark Lowe; M Bridget Zimmerman; Michael Wilschanski; Steven Werlin; David M Troendle; Uzma Shah; Sarah J Schwarzenberg; John F Pohl; Emily Perito; Chee Yee Ooi; Jaimie D Nathan; Veronique D Morinville; Brian A McFerron; Maria R Mascarenhas; Asim Maqbool; Quin Liu; Tom K Lin; Sohail Z Husain; Ryan Himes; Melvin B Heyman; Tanja Gonska; Matthew J Giefer; Cheryl E Gariepy; Steven D Freedman; Douglas S Fishman; Bradley Barth; Maisam Abu-El-Haija; Aliye Uc Journal: J Pediatr Gastroenterol Nutr Date: 2019-11 Impact factor: 2.839
Authors: Mateusz Gliwiński; Dorota Iwaszkiewicz-Grześ; Anna Wołoszyn-Durkiewicz; Monika Tarnowska; Magdalena Żalińska; Matylda Hennig; Hanna Zielińska; Anna Dukat-Mazurek; Joanna Zielkowska-Dębska; Maciej Zieliński; Anna Jaźwińska-Curyłło; Radosław Owczuk; Przemysława Jarosz-Chobot; Artur Bossowski; Agnieszka Szadkowska; Wojciech Młynarski; Natalia Marek-Trzonkowska; Grażyna Moszkowska; Janusz Siebert; Małgorzata Myśliwiec; Piotr Trzonkowski Journal: BMJ Open Diabetes Res Care Date: 2020-02
Authors: Shanshan Tang; Mingfeng Zhang; Samuel Zeng; Yaxun Huang; Melissa Qin; Ubaydah Nasri; Pere Santamaria; Arthur D Riggs; Liang Jin; Defu Zeng Journal: Proc Natl Acad Sci U S A Date: 2020-11-23 Impact factor: 11.205